Trevena

^{Priced, Nasdaq: TRVN}

Clinical-stage biotech developing treatments for pain and acute heart failure.

Industry: Health Care

First Day Return: -7.1%

TRVN

Clinical-stage biotech developing treatments for pain and acute heart failure.

IPO News for Trevena

US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs 02/03/14
UPDATED: Trevena prices upsized IPO at $7, as expected 01/30/14
Trevena decreases IPO price to $7 and increases shares offered, deal size is now $60 million 01/29/14

IPO Data
IPO Date	01/30/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$65
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.trevenainc.com
Headquarters	King of Prussia, PA, United States
Founded	2007
Employees at IPO	31

IPO News for Trevena

Trevena (TRVN) Performance